Renalytix AI is a health information services business based in the US. Renalytix AI shares (RNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.16 – an increase of 5.83% over the previous week.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.16 |
|---|---|
| 52-week range | $0.12 - $1.77 |
| 50-day moving average | $0.31 |
| 200-day moving average | $0.52 |
| Wall St. target price | $2.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.62 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.1561 from 2024-10-15
| 1 week (2024-10-09) | 5.83% |
|---|---|
| 1 month (2024-09-16) | -44.35% |
| 3 months (2024-07-16) | -54.61% |
| 6 months (2024-04-16) | -81.07% |
| 1 year (2023-10-16) | -87.71% |
|---|---|
| 2 years (2022-10-14) | -87.52% |
| 3 years (2021-10-15) | 24.66 |
| 5 years (2019-10-12) | N/A |
| Revenue TTM | $2.3 million |
|---|---|
| Gross profit TTM | $720,000 |
| Return on assets TTM | -93.54% |
| Return on equity TTM | -1073.18% |
| Profit margin | 0% |
| Book value | $-0.05 |
| Market Capitalization | $22.5 million |
TTM: trailing 12 months
We're not expecting Renalytix AI to pay a dividend over the next 12 months.
Over the last 12 months, Renalytix AI's shares have ranged in value from as little as $0.12 up to $1.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Renalytix AI's is 2.103. This would suggest that Renalytix AI's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.